Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd, Bathon J. Doyle MK, et al. Among authors: rahman mu. Semin Arthritis Rheum. 2009 Oct;39(2):123-31. doi: 10.1016/j.semarthrit.2008.08.002. Epub 2008 Sep 27. Semin Arthritis Rheum. 2009. PMID: 18823645 Review.
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, Beutler A, Doyle MK, Hsu B, Rahman MU. Hsia EC, et al. Among authors: rahman mu. Arthritis Rheum. 2012 Jul;64(7):2068-77. doi: 10.1002/art.34382. Arthritis Rheum. 2012. PMID: 22238071 Free article.
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU. Emery P, et al. Among authors: rahman mu. Arthritis Rheum. 2009 Aug;60(8):2272-83. doi: 10.1002/art.24638. Arthritis Rheum. 2009. PMID: 19644849 Free article. Clinical Trial.
Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.
Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, Aletaha D, Matteson EL, Conaghan PG, Keystone E, van der Heijde D, Smolen JS. Rahman MU, et al. Ann Rheum Dis. 2011 Sep;70(9):1631-40. doi: 10.1136/ard.2010.146043. Epub 2011 Jun 27. Ann Rheum Dis. 2011. PMID: 21708910 Free PMC article. Review.
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.
Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, Xu S, Rahman MU. Hsia EC, et al. Among authors: rahman mu. Arthritis Care Res (Hoboken). 2013 Feb;65(2):309-13. doi: 10.1002/acr.21788. Arthritis Care Res (Hoboken). 2013. PMID: 22782640 Free article. Clinical Trial.
196 results